✦ LIBER ✦

Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: An open label trial

✍ Scribed by Praveen Sharma; Ashish Kumar; Barjesh Chander Sharma; Shiv Kumar Sarin

Book ID: 116651770
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 239 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2008.10.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P038 AN OPEN-LABEL TRIAL OF INFLIXIMAB F

P038 AN OPEN-LABEL TRIAL OF INFLIXIMAB FOR INDUCING AND MAINTAINING CLINICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH ACUTE, SEVERE ULCERATIVE COLITIS

✍ G.J. Mantzaris; A. Roussos; S. Koilakou; A. Christidou; N. Viazis; N. Apostolou; 📂 Article 📅 2008 🏛 Oxford University Press ⚖ 97 KB

Efficacy and safety of infliximab vs. me

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

✍ J. Barker; M. Hoffmann; G. Wozel; J.-P. Ortonne; H. Zheng; H. van Hoogstraten; K 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 346 KB

W1257 Infliximab for Severe Ulcerative C

W1257 Infliximab for Severe Ulcerative Colitis: Short-Term and One Year Outcome of Three Dose Regimen. An Italian Multicentre Open-Label Study

✍ Monterubbianesi, Rita; Daperno, Marco; Armuzzi, Alessandro; Biancone, Livia; Cap 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Olanzapine monotherapy for acute depress

Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial

✍ William V. Bobo; Richard A. Epstein; Richard C. Shelton 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open‐label olanzapine monotherapy (mean modal dose, 15 mg/day) for 8 weeks. Assessments of psychopathology (Montgomery–Asb

P.80 INFLIXIMAB FOR SEVERE ULCERATIVE CO

P.80 INFLIXIMAB FOR SEVERE ULCERATIVE COLITIS: SHORT-TERM AND ONE YEAR OUTCOME OF THREE DOSE REGIMEN. AN ITALIAN MULTICENTRE OPEN-LABEL STUDY

✍ R. Monterubbianesi; M. Daperno; A. Armuzzi; L. Biancone; M. Cappello; A. Lavagna 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Efficacy and tolerability of fixed, low-

Efficacy and tolerability of fixed, low-dose combination therapy with verapamil sustained-release and trandolapril in patients with mild to severe essential hypertension uncontrolled by monotherapy: an open-label, multicenter trial

✍ Kamil Adalet; Hüseyin Oflaz; Alpay Sezer; Kemalettin Büyüköztürk 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 737 KB